SC Bio, a biopharmaceutical development company (CEO Chang-Hoon Lee) , announced on the 1st that it has successfully attracted a total of 14 billion won in Series B investment. This investment was participated by new investment institutions such as Union Investment Partners, Hyundai Technology Investment, Pioneer Investment, SL Investment, Kolon Investment, KDB Daewoo Infrastructure Asset Management, Enlight Ventures, and Xsquared, while existing investors I.M Investment Partners and Korea Investment Accelerator conducted follow-on investments.
Including this Series B round, SC Bio's cumulative investment totals 31 billion won. The company plans to use this funding to accelerate clinical trials for its flagship pipeline, R&D for follow-up pipelines, and global licensing negotiations.
SCB002, a small-molecule anticancer drug targeting Sirt6, one of SC Bio's key pipelines, has secured efficacy and safety in preclinical trials and is currently in the process of filing an Investigational New Drug (IND) application for Phase 1 clinical trials in Korea. Another immuno-oncology candidate, SCB001, is also being prepared for clinical trials within the next year.
In addition, the company is conducting preclinical trials for SCB003 and SCB010, which utilize its proprietary next-generation antibody-drug conjugate (ADC) platform technology. Market expectations for the related pipeline are also rising, as these drugs improve the toxicity limitations of existing ADC drugs.
Currently, SC Bio is a new drug development company with a diverse range of modalities, from small-molecule compounds to antibody-based therapeutics. It possesses the technological infrastructure to handle everything from new drug candidate optimization to most preclinical processes in-house. It operates dedicated centers for areas such as synthetic drug synthesis, pharmacological efficacy, pharmacodynamics, and toxicity assessment, and employs over 30 R&D personnel.
Park Joo-yeon, a senior partner at Union Investment Partners who led this investment, said, “SC Bio is a company that efficiently develops highly profitable targets through its internalized research infrastructure and has secured specialized personnel with commercialization potential,” adding, “After a long period of review, we decided to invest based on trust.”
CEO Lee Chang-hoon stated, "Despite a challenging investment environment, we were able to complete this meaningful round based on trust in our technological prowess and market potential." He added, "With the secured funds, we will focus on clinical development and pipeline advancement."
You must be logged in to post a comment.